mProX™ Human LILRB2 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

LILRB2, also known as ILT4, has been identified as a potential diagnostic and therapeutic target in various medical conditions. In diabetic retinopathy (DR), LILRB2 is one of the hub genes that have been identified as up-regulated in DR patients. It may serve as a potential point for the diagnosis and treatment of DR. LILRB2 has also been found to play a role in the interaction between amyloid-β 42 oligomers (AβO) and the LilrB2 receptor. This interaction is involved in changes in synaptic plasticity and cognitive deficits in Alzheimer's disease. Additionally, LILRB2 is associated with alloimmunisation susceptibility in sickle cell disease (SCD) patients. Polymorphisms of LILRB2 have been linked to the expression level of the receptor and its influence on inflammatory and immune response modulation. Furthermore, LILRB2 has been shown to promote tumor progression in triple-negative breast cancer (TNBC) by reprogramming glucose metabolism. It activates AKT-mTOR signaling, leading to the overexpression of glucose transporter 3 (GLUT3) and pyruvate kinase muscle 2 (PKM2), which are involved in aerobic glycolysis. Targeting LILRB2 may provide a promising strategy for combating TNBC. Overall, LILRB2 has diverse applications in the field of medicine, including as a diagnostic marker and therapeutic target in DR, Alzheimer's disease, SCD, and TNBC.